Matthew Ronsheim Entasis Therapeutics Holdings Inc. (ETTX) insider trading activity

Matthew Ronsheim is Chief of Pharma Sciences & MFG of Entasis Therapeutics Holdings Inc.. Currently has a direct ownership of 0 shares of ETTX, which is worth approximately $0. The most recent transaction as insider was on Jul 11, 2022, when has been sold 150,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Matthew Ronsheim Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 11 2022	SELL Sale (or disposition) back to the issuer	-	150,000 Reduced 100.0%	0 Common Stock
Jul 07 2022	SELL Disposition due to a tender of shares in a change of control transaction	$38,658 $2.2 p/Share	17,572 Reduced 100.0%	0 Common Stock
Jan 18 2022	BUY Grant, award, or other acquisition	-	125,000 Added 42.72%	167,572 Common Stock
Nov 02 2021	SELL Payment of exercise price or tax liability	$10,787 $2.94 p/Share	3,669 Reduced 7.93%	42,572 Common Stock
Oct 19 2021	SELL Open market or private sale	$11,991 $3.19 p/Share	3,759 Reduced 7.52%	46,241 Common Stock
Oct 19 2021	BUY Grant, award, or other acquisition	-	25,000 Added 33.33%	50,000 Common Stock
Jan 15 2021	BUY Grant, award, or other acquisition	-	25,000 Added 50.0%	25,000 Common Stock

Also insider at

INVA

Innoviva, Inc. Healthcare